ME03817B - Prolekovi gemcitabina - Google Patents
Prolekovi gemcitabinaInfo
- Publication number
- ME03817B ME03817B MEP-2020-171A MEP2020171A ME03817B ME 03817 B ME03817 B ME 03817B ME P2020171 A MEP2020171 A ME P2020171A ME 03817 B ME03817 B ME 03817B
- Authority
- ME
- Montenegro
- Prior art keywords
- cancer
- pharmaceutical formulation
- formulation according
- alaninyl
- benzoxy
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 229910019142 PO4 Inorganic materials 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 239000010452 phosphate Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000728 Thymus Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000013011 aqueous formulation Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003495 polar organic solvent Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 201000009377 thymus cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Claims (11)
1. Farmaceutska formulacija koja sadrži gemcitabin-[fenil-benzoksi-L-alaninil)]-(S)-fosfat 3: ili njegovu farmaceutski prihvatljivu so ili solvat, koji ima diastereoizomernu čistoću veću od 90% i najmanje jedan farmaceutski prihvatljiv ekscipijens; pri čemu je formulacija vodena formulacija koja takode sadrži polarni organski rastvarač.
2. Farmaceutska formulacija prema patentnom zahtevom 1, naznačena time što je formulacija pogodna za parenteralnu primenu.
3. Farmaceutska formulacija prema patentnom zahtevu 2, naznačena time što je formulacija pogodna za intravensku primenu.
4. Farmaceutska formulacija prema bilo kom od patentnih zahteva 1 do 3, naznačena time što formulacija dodatno sadrži ciklodekstrin.
5. Farmaceutska formulacija prema patentnom zahtevu 1, naznačena time što je formulacija pogodna za oralnu primenu.
6. Farmaceutska formulacija prema bilo kom prethodnom patentnom zahtevu, naznačena time što je gemcitabin-[fenil-benzoksi-L-alaninil)]-(S)-fosfat 3 u obliku slobodne haze.
7. Farmaceutska formulacija prema bilo kom prethodnom patentnom zahtevu, naznacena timesto gemcitabin-[fenil-benzoksi-L-alaninil)]-(5)-fosfat 3 ima diastereoizomemu cistocu vecu od95%.
8. Farmaceutska formulacija prema patentnom zahtevu 7, naznačena time što gemcitabin-[fenil-benzoksi-L-alaninil)]-(5)-fosfat 3 ima diastereoizomemu čistoću veću od 98%.
9. Farmaceutska formulacija prema patentnom zahtevu 8, naznačena time što gemcitabin-[fenil-benzoksi-L-alaninil)]-(5)-fosfat 3 ima diastereoizomemu cistocu vecu od 99.5%.
10. Farmaceutska formulacija prema bilo kom porethodnom patentnom zahtevu, za upotrebu u lečenju kancera.
11. Farmaceutska formulacija za upotrebu prema patentnom zahtevu 10, naznačena time što kancer je izabran od: kancera pankreasa, kancera dojke, kancera jajnika, kancera bešike, kolorektalnog kancera, kancera pluća, kancera bešike, kancera prostate, holangiokarcinoma, kancera bubrega, cervikalnog kancera, kancera timusa, kancera nepoznatog primamog porekla, limfoma ili leukemije.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2050MU2014 | 2014-06-25 | ||
| GBGB1411253.6A GB201411253D0 (en) | 2014-06-25 | 2014-06-25 | Prodrug |
| PCT/GB2015/051857 WO2015198058A1 (en) | 2014-06-25 | 2015-06-25 | Gemcitabine prodrugs |
| EP15733497.0A EP3160978B1 (en) | 2014-06-25 | 2015-06-25 | Gemcitabine prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03817B true ME03817B (me) | 2021-04-20 |
Family
ID=53499027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2020-171A ME03817B (me) | 2014-06-25 | 2015-06-25 | Prolekovi gemcitabina |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US10662213B2 (me) |
| EP (2) | EP3160978B1 (me) |
| JP (2) | JP6982957B2 (me) |
| KR (2) | KR102563040B1 (me) |
| CN (2) | CN111214480A (me) |
| AU (2) | AU2015278899B2 (me) |
| CA (1) | CA2945938C (me) |
| CL (1) | CL2016003260A1 (me) |
| CY (1) | CY1123389T1 (me) |
| DK (1) | DK3160978T3 (me) |
| EA (1) | EA034890B1 (me) |
| ES (2) | ES2811268T3 (me) |
| HR (2) | HRP20201264T1 (me) |
| HU (2) | HUE062474T2 (me) |
| IL (2) | IL248642B (me) |
| LT (1) | LT3160978T (me) |
| ME (1) | ME03817B (me) |
| MX (2) | MX2016015628A (me) |
| MY (1) | MY183198A (me) |
| NZ (2) | NZ765508A (me) |
| PH (1) | PH12016502553B1 (me) |
| PL (1) | PL3160978T3 (me) |
| PT (1) | PT3160978T (me) |
| RS (1) | RS60968B1 (me) |
| SG (2) | SG11201608808TA (me) |
| SI (1) | SI3160978T1 (me) |
| SM (1) | SMT202000564T1 (me) |
| TW (2) | TWI695718B (me) |
| WO (1) | WO2015198058A1 (me) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104903339A (zh) | 2012-11-16 | 2015-09-09 | 卡迪夫大学学院顾问有限公司 | 用于制备核苷前体药物的方法 |
| PL3160978T3 (pl) | 2014-06-25 | 2020-11-30 | NuCana plc | Proleki gemcytabiny |
| EA033046B1 (ru) | 2014-06-25 | 2019-08-30 | НУКАНА ПиЭлСи | Состав, содержащий пролекарство гемцитабина |
| GB201417644D0 (en) | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
| CN112156102B (zh) | 2015-09-16 | 2023-10-03 | 济南高合医疗科技有限公司 | 一种nuc-1031单一异构体的晶型及其制备方法 |
| CN106543252A (zh) * | 2015-09-16 | 2017-03-29 | 博瑞生物医药（苏州）股份有限公司 | 核苷氨基磷酸酯类前药的制备方法及其中间体 |
| CN106543220A (zh) | 2015-09-16 | 2017-03-29 | 博瑞生物医药（苏州）股份有限公司 | 氨基磷酸酯化合物及其制备方法和晶体 |
| WO2017060661A1 (en) | 2015-10-05 | 2017-04-13 | Nucana Biomed Limited | Combination therapy |
| SG11201804774YA (en) | 2015-12-11 | 2018-07-30 | NuCana plc | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 |
| GB201522771D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Crystalline form of a phosphate derivative |
| GB201609600D0 (en) * | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| WO2018019188A1 (zh) * | 2016-07-23 | 2018-02-01 | 博瑞生物医药（苏州）股份有限公司 | 核苷氨基磷酸酯类前药的多晶型及其制备方法 |
| CN106946960A (zh) * | 2017-03-29 | 2017-07-14 | 郑州泰基鸿诺医药股份有限公司 | 一种吉西他滨前药的晶型、制备方法、用途和药物组合物 |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| CN110806454A (zh) * | 2018-08-06 | 2020-02-18 | 江苏正大清江制药有限公司 | 一种盐酸吉西他滨中手性异构体的检测方法 |
| CN110215469B (zh) * | 2019-07-08 | 2021-11-30 | 绍兴市人民医院 | 一种治疗胆管癌的药物组合物 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
| US5827727A (en) | 1990-02-01 | 1998-10-27 | Emory University | Method of resolution of 1,3-oxathiolane nucleoside enantiomers |
| US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| IL137164A0 (en) | 1998-01-23 | 2001-07-24 | Newbiotics Inc | Enzyme catalyzed therapeutic agents |
| CN1390227A (zh) | 1999-07-22 | 2003-01-08 | 新生物生物公司 | 酶催化的治疗活化 |
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| AU2006208109A1 (en) | 2005-01-27 | 2006-08-03 | Erimos Pharmaceuticals Llc | Formulations for injection of catecholic butanes, including NDGA compounds, into animals |
| CA2618335C (en) | 2005-08-15 | 2015-03-31 | F.Hoffmann-La Roche Ag | Antiviral phosphoramidates of 4'-substituted pronucleotides |
| CA2635797C (en) | 2006-02-09 | 2015-03-31 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
| GB0821994D0 (en) * | 2008-12-02 | 2009-01-07 | Ge Healthcare Ltd | In viva imaging method |
| JP2012514657A (ja) | 2009-01-09 | 2012-06-28 | ユニバーシテイ・カレツジ・オブ・カーデイフ・コンサルタンツ・リミテツド | ウィルス感染を治療するためのグアノシンヌクレオシド化合物のホスホルアミダート誘導体 |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| AU2010322516A1 (en) | 2009-11-20 | 2012-05-17 | Clavis Pharma Asa | Parenteral formulations of gemcitabine derivatives |
| CA2810928A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| SI2681227T1 (sl) | 2011-03-01 | 2016-04-29 | Nucana Biomed Limited | Fosforamidatni derivati 5-fluoro-2'-deoksiuridina za uporabo pri zdravljenju raka |
| AU2012366932B2 (en) | 2012-01-20 | 2017-02-02 | Aratana Therapeutics, Inc. | Eye drop composition |
| CN104903339A (zh) | 2012-11-16 | 2015-09-09 | 卡迪夫大学学院顾问有限公司 | 用于制备核苷前体药物的方法 |
| GB2517988A (en) * | 2013-09-09 | 2015-03-11 | Redx Pharma Ltd | Compounds |
| PL3043803T3 (pl) | 2013-09-11 | 2022-11-07 | Emory University | Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie |
| WO2015081133A2 (en) * | 2013-11-27 | 2015-06-04 | Idenix Pharmaceuticals, Inc. | Nucleotides for the treatment of liver cancer |
| EA033046B1 (ru) * | 2014-06-25 | 2019-08-30 | НУКАНА ПиЭлСи | Состав, содержащий пролекарство гемцитабина |
| PL3160978T3 (pl) | 2014-06-25 | 2020-11-30 | NuCana plc | Proleki gemcytabiny |
| JP6646663B2 (ja) | 2014-07-22 | 2020-02-14 | ニューカナ バイオメッド リミテッドＮｕｃａｎａ Ｂｉｏｍｅｄ Ｌｉｍｉｔｅｄ | ゲムシタビン−［フェニル（ベンゾキシ−ｌ−アラニニル）］ホスフェートの製造方法リン酸誘導体を製造する方法 |
| GB201417644D0 (en) | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
| KR20180021697A (ko) | 2015-05-14 | 2018-03-05 | 뉴카나 피엘씨 | 암 치료 |
| WO2017060661A1 (en) | 2015-10-05 | 2017-04-13 | Nucana Biomed Limited | Combination therapy |
| SG11201804774YA (en) | 2015-12-11 | 2018-07-30 | NuCana plc | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 |
| CA3008749C (en) | 2015-12-23 | 2024-01-02 | NuCana plc | Treatment of ovarian cancer or biliary tract cancer with a combination of gemcitabine-(phenyl-benzoxy-l-alaninyl)]-phosphate and cisplatin |
| GB201522771D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Crystalline form of a phosphate derivative |
| CA3008769A1 (en) | 2015-12-23 | 2017-06-29 | NuCana plc | Combination therapy comprising nuc-1031 and cisplatin |
-
2015
- 2015-06-25 PL PL15733497T patent/PL3160978T3/pl unknown
- 2015-06-25 ES ES15733497T patent/ES2811268T3/es active Active
- 2015-06-25 HR HRP20201264TT patent/HRP20201264T1/hr unknown
- 2015-06-25 KR KR1020227019095A patent/KR102563040B1/ko active Active
- 2015-06-25 US US15/308,491 patent/US10662213B2/en active Active
- 2015-06-25 NZ NZ765508A patent/NZ765508A/en unknown
- 2015-06-25 JP JP2016573536A patent/JP6982957B2/ja not_active Expired - Fee Related
- 2015-06-25 DK DK15733497.0T patent/DK3160978T3/da active
- 2015-06-25 NZ NZ725205A patent/NZ725205A/en unknown
- 2015-06-25 HR HRP20230584TT patent/HRP20230584T1/hr unknown
- 2015-06-25 SG SG11201608808TA patent/SG11201608808TA/en unknown
- 2015-06-25 ME MEP-2020-171A patent/ME03817B/me unknown
- 2015-06-25 MX MX2016015628A patent/MX2016015628A/es unknown
- 2015-06-25 AU AU2015278899A patent/AU2015278899B2/en not_active Ceased
- 2015-06-25 MX MX2021001140A patent/MX391758B/es unknown
- 2015-06-25 WO PCT/GB2015/051857 patent/WO2015198058A1/en not_active Ceased
- 2015-06-25 CA CA2945938A patent/CA2945938C/en active Active
- 2015-06-25 KR KR1020167033632A patent/KR102407935B1/ko active Active
- 2015-06-25 TW TW104120671A patent/TWI695718B/zh not_active IP Right Cessation
- 2015-06-25 CN CN202010140546.2A patent/CN111214480A/zh active Pending
- 2015-06-25 SG SG10201907898SA patent/SG10201907898SA/en unknown
- 2015-06-25 CN CN201580034740.XA patent/CN106459129B/zh active Active
- 2015-06-25 HU HUE20187951A patent/HUE062474T2/hu unknown
- 2015-06-25 ES ES20187951T patent/ES2948660T3/es active Active
- 2015-06-25 MY MYPI2016002193A patent/MY183198A/en unknown
- 2015-06-25 EP EP15733497.0A patent/EP3160978B1/en active Active
- 2015-06-25 TW TW109115415A patent/TWI758728B/zh not_active IP Right Cessation
- 2015-06-25 SM SM20200564T patent/SMT202000564T1/it unknown
- 2015-06-25 PT PT157334970T patent/PT3160978T/pt unknown
- 2015-06-25 EP EP20187951.7A patent/EP3757112B1/en active Active
- 2015-06-25 HU HUE15733497A patent/HUE053240T2/hu unknown
- 2015-06-25 LT LTEP15733497.0T patent/LT3160978T/lt unknown
- 2015-06-25 RS RS20200953A patent/RS60968B1/sr unknown
- 2015-06-25 EA EA201692312A patent/EA034890B1/ru unknown
- 2015-06-25 SI SI201531314T patent/SI3160978T1/sl unknown
-
2016
- 2016-10-31 IL IL248642A patent/IL248642B/en active IP Right Grant
- 2016-12-20 CL CL2016003260A patent/CL2016003260A1/es unknown
- 2016-12-20 PH PH12016502553A patent/PH12016502553B1/en unknown
-
2019
- 2019-08-13 AU AU2019216626A patent/AU2019216626B2/en not_active Ceased
-
2020
- 2020-02-17 IL IL272724A patent/IL272724B/en active IP Right Grant
- 2020-04-22 JP JP2020076384A patent/JP6970236B2/ja not_active Expired - Fee Related
- 2020-05-04 US US16/865,527 patent/US11629164B2/en active Active
- 2020-08-10 CY CY20201100745T patent/CY1123389T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME03817B (me) | Prolekovi gemcitabina | |
| MX2022001755A (es) | Compuestos de dinucleotidos ciclicos y metodos de uso. | |
| NZ780890A (en) | Pharmaceutical compositions comprising meloxicam | |
| MX2018002520A (es) | Compuesto novedoso de pirazolo[3,4-d] pirimidina o sal del mismo. | |
| EP4389227A3 (en) | Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders | |
| CA3018932C (en) | Pharmaceutical combinations for the treatment of cancer | |
| MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
| WO2015081133A3 (en) | Nucleotides for the treatment of liver cancer | |
| TN2017000511A1 (en) | New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them. | |
| CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
| GEP20237470B (en) | Magl inhibitors | |
| WO2016080810A3 (ko) | 바이구아나이드 화합물 및 이의 용도 | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| PH12019501178A1 (en) | Thiopene derivatives as antiviral agents | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| PH12017502046A1 (en) | Salts and prodrugs of 1-methyl-d-tryptophan | |
| NZ722345A (en) | Pyrazolone compounds and uses thereof | |
| WO2016001905A3 (en) | Stable liquid ready-to-use injectable formulation of bortezomib | |
| MX374725B (es) | Composiciones farmacéuticas que comprenden derivado de fenilaminopirimidina. | |
| WO2014122460A3 (en) | Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes | |
| CY1119522T1 (el) | (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| ZA202107580B (en) | Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4- methoxybenzylsulphone with enhanced stability and bioavailability | |
| MX2017002544A (es) | Derivados de isoquinolinona utiles en el tratamiento contra el cancer. | |
| MX2017002627A (es) | Derivados de polieteres macrociclicos de n-aril-2-amino-4-aril-pir imidina como inhibidores de ftl3 y jak. | |
| IL261929B (en) | Stable pharmaceutical preparations for topical administration and their use |